Corridor Pharmaceuticals
Towson
About Corridor Pharmaceuticals
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $27.6M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Jan 2013)
- Website: corridorpharma.com
- Phone: +1 410-616-0804
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/corridor-pharmaceuticals-1202041 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.